A novel 28-amino-acid peptide from tarantula venom lowered blood glucose, stimulated insulin secretion, protected beta cells, and enhanced appetite suppression when combined with exenatide in mice.
Triple benefit at 250 nmol/kgA single dose of the tarantula venom peptide lowered blood glucose, stimulated glucose-dependent insulin secretion, and significantly reduced appetite in mice.
What the researchers found
The novel 28-amino-acid peptide Δ-TRTX-AC1, isolated from Aphonopelma chalcodes tarantula venom, demonstrated multiple beneficial effects: it evoked glucose-dependent insulin secretion from beta cells via KATP and calcium channel signaling pathways, enhanced beta-cell proliferation, and provided significant protection against cytokine-induced apoptosis.
In C57BL/6 mice at 250 nmol/kg, Δ-TRTX-AC1 decreased blood glucose levels and produced a significant satiating effect. While it did not enhance exenatide's glucose-lowering effects, it significantly augmented exenatide-mediated appetite suppression, suggesting complementary mechanisms of action. The peptide adopted a characteristic inhibitor cysteine knot (ICK) structure and was non-toxic to beta cells.
Why it matters
The diabetes drug exenatide was originally discovered in Gila monster venom, proving that venomous animals are a rich source of therapeutic peptides. This study extends that approach to tarantula venom, identifying a peptide with a unique combination of benefits — insulin secretion, beta-cell protection, and appetite suppression — that could complement existing GLP-1 therapies for diabetes and obesity.
How the study worked
Researchers isolated and sequenced the peptide from tarantula venom, then synthesized it and confirmed its structure. They tested safety and insulin-secretory effects in BRIN BD11 cells and murine pancreatic islets, investigating signaling pathways (KATP channels, calcium channels). Beta-cell proliferation and protection against cytokine-induced apoptosis were assessed. In vivo effects on blood glucose and satiety were tested in C57BL/6 mice, alone and in combination with exenatide.
What this study cannot tell us
All experiments were conducted in vitro or in normal (non-diabetic) mice, so efficacy in diabetic models or humans is unknown. The mechanism of the appetite-suppressing effect was not fully elucidated. Only acute single-dose effects were tested — chronic dosing safety and sustained efficacy need evaluation. The peptide's pharmacokinetics (how long it lasts in the body) were not detailed.
How to read the evidence
This is an early-stage preclinical study demonstrating proof-of-concept in cell cultures and normal mice. While the results are promising across multiple endpoints, translation to diabetic models and human trials is needed before clinical relevance can be established.
When this study was published
Published in 2023, this represents recent work in the active field of venom-derived peptide therapeutics, building on the success of exenatide discovered decades earlier.
The bigger picture
Venom-derived peptides have already revolutionized diabetes treatment through exenatide (Byetta). This discovery expands the search to spider venoms, which contain thousands of understudied bioactive peptides. The finding that Δ-TRTX-AC1 enhances exenatide's appetite-suppressing effects without duplicating its glucose-lowering action suggests it could become a complementary therapy, addressing diabetes and obesity through distinct mechanisms.
Questions still open
- What is the specific mechanism by which Δ-TRTX-AC1 suppresses appetite, and does it involve the same pathways as GLP-1 receptor agonists?
- Would this peptide show sustained benefits in chronic diabetic mouse models over weeks of treatment?
- Could the complementary appetite-suppressing effects with exenatide lead to a combination therapy for obesity?
Common questions
How did researchers find a diabetes peptide in tarantula venom?
Could this tarantula venom peptide work alongside existing diabetes drugs?
Read the original research
A novel peptide isolated from Aphonopelma chalcodes tarantula venom with benefits on pancreatic islet function and appetite control.
Biochemical pharmacology, 212, 115544
Citation
Coulter-Parkhill, A; Dobbin, Swm; Tanday, N; Gault, V A; McClean, S; Irwin, N. (2023). A novel peptide isolated from Aphonopelma chalcodes tarantula venom with benefits on pancreatic islet function and appetite control.. Biochemical pharmacology, 212, 115544. https://doi.org/10.1016/j.bcp.2023.115544